Abstract
Nonsteroidal anti-inflammatory drugs (NSAID)s relieve pain, inflammation, and fever by inhibiting the activity of cyclooxygenase isozymes (COX-1 and COX-2). Despite their clinical efficacy, NSAIDs can cause gastrointestinal (GI) and cardiovascular (CV) complications. Moreover, NSAID use is characterized by a remarkable individual variability in the extent of COX isozyme inhibition, therapeutic efficacy, and incidence of adverse effects. The interaction between the gut microbiota and host has emerged as a key player in modulating host physiology, gut microbiota-related disorders, and metabolism of xenobiotics. Indeed, host-gut microbiota dynamic interactions influence NSAID disposition, therapeutic efficacy, and toxicity. The gut microbiota can directly cause chemical modifications of the NSAID or can indirectly influence its absorption or metabolism by regulating host metabolic enzymes or processes, which may have consequences for drug pharmacokinetic and pharmacodynamic properties. NSAID itself can directly impact the composition and function of the gut microbiota or indirectly alter the physiological properties or functions of the host which may, in turn, precipitate in dysbiosis. Thus, the complex interconnectedness between host-gut microbiota and drug may contribute to the variability in NSAID response and ultimately influence the outcome of NSAID therapy. Herein, we review the interplay between host-gut microbiota and NSAID and its consequences for both drug efficacy and toxicity, mainly in the GI tract. In addition, we highlight progress towards microbiota-based intervention to reduce NSAID-induced enteropathy.
Introduction
Nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, aspirin, and naproxen are among the most widely used medications globally. While effective for pain and inflammation, their use is frequently associated with gastrointestinal (GI) complications, ranging from mild indigestion to life-threatening ulcers and enteropathy. A significant challenge in clinical practice is the massive individual variability in drug response and toxicity. Recent research suggests that the gut microbiota—the trillions of microbes in our digestive tract—is a primary driver of this variability, creating a complex "host–microbiota–drug" triangle.
Mechanisms of Interaction: The Two-Way Street
The relationship between NSAIDs and the gut microbiota is bidirectional. The microbiota can dictate drug metabolism and toxicity, while NSAIDs simultaneously trigger "dysbiosis," a microbial imbalance that exacerbates tissue damage.
The Enterohepatic "Boomerang" Effect
A critical mechanism of toxicity involves the enterohepatic circulation. Many NSAIDs are deactivated in the liver via glucuronidation and excreted into the bile. However, certain gut bacteria produce the enzyme β-glucuronidase, which removes the protective sugar molecule, reactivating the drug directly in the small intestine. This local reactivation is a major cause of NSAID-induced mucosal lesions.
NSAID-Induced Dysbiosis
NSAIDs can act as direct antimicrobial agents, inhibiting the growth of beneficial bacteria and shifting the microbial community toward a pro-inflammatory state. This shift often involves an increase in Gram-negative bacteria and a decrease in protective strains like Lactobacillus, leading to increased intestinal permeability ("leaky gut") and systemic inflammation.
As shown in the data above, different NSAIDs produce distinct microbial signatures. For instance, indomethacin treatment in rats has been shown to increase Enterococcus faecalis while decreasing segmented filamentous bacteria, whereas naproxen use in rats leads to a decrease in Lachnospiraceae.
Therapeutic Interventions and Precision Medicine
Understanding these interactions opens new avenues for mitigating NSAID toxicity:
- Antibiotics: Rodent studies have shown that broad-spectrum antibiotics can significantly reduce the severity of NSAID-induced intestinal lesions by eliminating the bacteria responsible for drug reactivation.
- Probiotics: Clinical trials in humans have demonstrated that supplementation with strains like Lactobacillus casei Shirota can decrease mucosal lesions in patients taking low-dose aspirin.
- Targeted Inhibitors: A promising area of research involves small-molecule inhibitors that specifically target bacterial β-glucuronidase without affecting the host's enzymes, potentially preventing ulcers while maintaining the drug's systemic efficacy.
- Mucosal Protectors: Agents like rebamipide have been found to "reset" the microbiota, increasing beneficial Lactobacillales and decreasing harmful Clostridium.
Limitations and Future Directions
While the link between the microbiota and NSAID response is clear, most mechanistic data currently stems from rodent models, which do not perfectly mirror human physiology. Future research must move toward longitudinal human studies and a more holistic view of the microbiome, including the mycobiome (fungi) and virome (viruses). The ultimate goal is to profile a patient's unique microbial signature to prescribe the safest and most effective analgesic regimen.
Summary updated